3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
1303
Carcinoma, Renal Cell
658
Urinary Bladder Neoplasms
405
Carcinoma, Non-Small-Cell Lung
331
Neoplasms
300
Carcinoma, Transitional Cell
262
Breast Neoplasms
252
Ovarian Neoplasms
247
Melanoma
235
Colorectal Neoplasms
224
Neoplasm Metastasis
214
Kidney Neoplasms
200
Pancreatic Neoplasms
169
Stomach Neoplasms
161
Squamous Cell Carcinoma of Head and Neck
141
Lung Neoplasms
140
Uterine Cervical Neoplasms
121
Non-Muscle Invasive Bladder Neoplasms
118
Head and Neck Neoplasms
111
Triple Negative Breast Neoplasms
110
Endometrial Neoplasms
108
Esophageal Neoplasms
106
Carcinoma, Hepatocellular
95
Small Cell Lung Carcinoma
78
Sarcoma
75
Colonic Neoplasms
55
Urologic Neoplasms
53
Prostatic Neoplasms, Castration-Resistant
47
Liver Neoplasms
47
Carcinoma
43
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biochemically Recurrent Prostate Cancer
×
Genitourinary
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts